Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Simple Summary A new class of drugs, termed Immune Checkpoint Inhibitors, has
revolutionized cancer therapy during the last few years. Unfortunately, these drugs are only …

Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses,
revealing mutational signatures, imprints of DNA damage, and repair processes that have …

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …

The immune system can recognize and attack cancer cells, especially those with a high load
of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair …

Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with
mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer …

The resurgence of immune therapies in cancer medicine has elicited a corresponding
interest in understanding the basis of patient response or resistance to these treatments …

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …

Simple Summary A subset of colorectal cancers (CRCs) is characterized by a mismatch
repair deficiency that is frequently associated with microsatellite instability (MSI). The …

Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response
(DDR) is emerging as a promising therapeutic strategy in different solid tumors. The …